Emerging strategies for exploiting cannabinoid receptor agonists as medicines

British Journal of Pharmacology

Volumn 156, Issue 3, 2009, Pages 397-411

  Pertwee, Roger G ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

9 tetrahydrocannabinol; Blood brain barrier; Cannabinoid receptor agonism; Cannabis; CB 1 receptors; CB 2 receptors; Clinical applications; Clinical strategies; Endocannabinoid system; Synergistic interactions

Indexed keywords

1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 2 METHYL 3 (1 NAPHTHOYL) 1 PROPYLINDOLE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 3 (2 IODO 5 NITROBENZOYL) 1 (1 METHYL 2 PIPERIDINYLMETHYL)INDOLE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; AJULEMIC ACID; ARACHIDONYLCYCLOPROPYLAMIDE; BUPIVACAINE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOL; CANNABIS; CLONIDINE; CODEINE; COMPOUND A; DEXANABINOL; DEXMEDETOMIDINE; DIAZEPAM; DRONABINOL; FENTANYL; IMIPRAMINE; INDOMETACIN; MORPHINE; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NABILONE; NAPHTHALEN 1 YL (4 PENTYLOXYNAPHTHALEN 1 YL)METHANONE; NEOSTIGMINE; NICOTINE; ONDANSETRON; UNCLASSIFIED DRUG; UNINDEXED DRUG; DRUG DERIVATIVE; LIGAND; PLANT EXTRACT; TETRAHYDROCANNABINOL; TETRAHYDROCANNABINOL CANNABIDIOL COMBINATION; TETRAHYDROCANNABINOL-CANNABIDIOL COMBINATION;

ANALGESIA; BALANCE IMPAIRMENT; BLOOD BRAIN BARRIER; BLURRED VISION; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CONCENTRATION LOSS; CONFUSION; CONSTIPATION; DEPRESSION; DIARRHEA; DISORIENTATION; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG TARGETING; DRUNKENNESS; DYSPHORIA; FATIGUE; HALLUCINATION; HEART PALPITATION; HUMAN; HYPOTENSION; LOW DRUG DOSE; MEMORY DISORDER; MULTIPLE SCLEROSIS; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NEUROPATHIC PAIN; NONHUMAN; PAIN; PARANOIA; PRIORITY JOURNAL; RECEPTOR UPREGULATION; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; SWEATING; TREMOR; XEROSTOMIA; DRUG INTERACTION; DRUG POTENTIATION; METABOLISM;

BLOOD-BRAIN BARRIER; DRUG INTERACTIONS; HUMANS; LIGANDS; PLANT EXTRACTS; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; TETRAHYDROCANNABINOL;

EID: 65449146377     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2008.00048.x     Document Type: Review

References (154)

1. Adam L, Salois D, Rihakova L, Lapointe S, St-Onge S, Labrecque J et al. (2007). Positive allosteric modulators of CB1 receptors. Symposium on the Cannabinoids. Burlington, Vermont, USA. International Cannabinoid Research Society, p. 86.
2. Adamczyk P, Golda A, McCreary AC, Filip M, Przegalnski E (2008). Activation of endocannabinoid transmission induces antidepressant-like effects in rats. J Physiol Pharmacol 59 : 217 228.
3. Ahn DK, Choi HS, Yeo SP, Woo YW, Lee MK, Yang GY et al. (2007). Blockade of central cyclooxygenase (COX) pathways enhances the cannabinold-induced antinociceptive effects on inflammatory temporomandibular joint (TMJ) nociception. Pain 132 : 23 32.
4. Alexander SPH, Mathie A, Peters JA (2008). Guide to receptors and channels (GRAC). Br J Pharmacol 153 (Suppl. 2 S1 S209.
5. 2-selective ligands. FEBS Lett 580 : 568 574.
6. 2 receptor expression in the rat brainstem cochlear and vestibular nuclei. Acta Oto-Laryngol 128 : 961 967.
7. Balerio GN, Aso E, Maldonado R (2006). Role of the cannabinoid system in the effects induced by nicotine on anxiety-like behaviour in mice. Psychopharmacology 184 : 504 513.
8. Bambico FR, Katz N, Debonnel G, Gobbi G (2007). Cannabinoids elicit antidepressant-like behavior and activate serotonergic neurons through the medial prefrontal cortex. J Neurosci Res 27 : 11700 11711.
9. Beltramo M, Bernardini N, Bertorelli R, Campanella M, Nicolussi E, Fredduzzi S et al. (2006). CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms. Eur J Neurosci 23 : 1530 1538.
10. 2) selective ligand AM1241 and its resolved enantiomers. Br J Pharmacol 151 : 1061 1070.
11. Boyce S (2008). Targeting peripheral cannabinoid 1 (CB1) receptors for chronic pain. Fundam Clin Pharmacol 22 (Suppl. 2 12.
12. Brady CM, DasGupta R, Dalton C, Wiseman OJ, Berkley KJ, Fowler CJ (2004). An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. Mult Scler 10 : 425 433.
13. 9-tetrahydrocannabinol and AM 404, the anandamide transport inhibitor, in Sprague-Dawley rats. Eur J Pharmacol 555 : 156 163.
14. Cabral GA, Staab A (2005). Effects on the immune system. In : Pertwee RG (ed.). Cannabinoids. Handbook of Experimental Pharmacology, Vol. 168. Springer-Verlag : Heidelberg, pp. 385 423.
15. Cichewicz DL (2004). Synergistic interactions between cannabinoid and opioid analgesics. Life Sci 74 : 1317 1324.
16. 9-tetrahydrocannabinol and opioids after oral administration. J Pharmacol Exp Ther 304 : 1010 1015.
17. 9- tetrahydrocannabinol. Eur J Pharmacol 525 : 74 82.
18. 1 cannabinoid and GABAB receptor interactions in rat hippocampal membranes. Neurochem Int 52 : 1402 1409.
19. 9- tetrahydrocannabinol and morphine in the arthritic rat. Eur J Pharmacol 567 : 125 130.
20. De Vry J, Jentzsch KR, Kuhl E, Eckel G (2004). Behavioral effects of cannabinoids show differential sensitivity to cannabinoid receptor blockade and tolerance development. Behav Pharmacol 15 : 1 12.
21. Desai BS, Monahan AJ, Carvey PM, Hendey B (2007). Blood-brain barrier pathology in Alzheimer's and Parkinson's disease: implications for drug therapy. Cell Transplant 16 : 285 299.
22. Després J-P, Golay A, Sjöström L (2005). Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353 : 2121 2134.
23. Després J-P, Lemieux I, Alméras N (2006). Contribution of CB1 blockade to the management of high-risk abdominal obesity. Int J Obes 30 : S44 S52.
24. Devane WA, Hanuš L, Breuer A, Pertwee RG, Stevenson LA, Griffin G et al. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258 : 1946 1949.
25. Di Marzo V (2008). Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discov 7 : 438 455.
26. Di Marzo V, De Petrocellis L, Bisogno T (2005). The biosynthesis, fate and pharmacological properties of endocannabinoids. In : Pertwee RG (ed.). Cannabinoids. Handbook of Experimental Pharmacology, Vol. 168. Springer-Verlag : Heidelberg, pp. 147 185.
27. 2 receptor. Br J Pharmacol 153 : 271 276.
28. Dogrul A, Gul H, Akar A, Yildiz O, Bilgin F, Guzeldemir E (2003). Topical cannabinoid antinociception: synergy with spinal sites. Pain 105 : 11 16. (Pubitemid 37167991)
29. 2 receptors in the enteric nervous system modulate gastrointestinal contractility in lipopolysaccharide-treated rats. Am J Physiol Gastrointest Liver Physiol 295 : G78 G87.
30. Dvorak M, Watkinson A, McGlone F, Rukwied R (2003). Histamine induced responses are attenuated by a cannabinoid receptor agonist in human skin. Inflamm Res 52 : 238 245.
31. Dyson A, Peacock M, Chen A, Courade J-P, Yaqoob M, Groarke A et al. (2005). Antihyperalgesic properties of the cannabinoid CT-3 in chronic neuropathic and inflammatory pain states in the rat. Pain 116 : 129 137.
32. 2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration. J Med Chem 50 : 3851 3856.
33. 9-tetrahydrocannabinol-induced catalepsy-like immobilization in mice. Eur J Pharmacol 550 : 117 122.
34. Ellgren M, Spano SM, Hurd YL (2007). Adolescent cannabis exposure alters opiate intake and opioid limbic neuronal populations in adult rats. Neuropsychopharmacology 32 : 607 615.
35. Finn DP, Beckett SRG, Roe CH, Madjd A, Fone KCF, Kendall DA et al. (2004). Effects of coadministration of cannabinoids and morphine on nociceptive behaviour, brain monoamines and HPA axis activity in a rat model of persistent pain. Eur J Neurosci 19 : 678 686.
36. Fox A, Bevan S (2005). Therapeutic potential of cannabinoid receptor agonists as analgesic agents. Expert Opin Investig Drugs 14 : 695 703.
37. Gholizadeh S, Shafaroodi H, Ghasemi M, Bahremand A, Sharifzadeh M, Dehpour AR (2007). Ultra-low dose cannabinoid antagonist AM251 enhances cannabinoid anticonvulsant effects in the pentylenetetrazole-induced seizure in mice. Neuropharmacology 53 : 763 770.
38. Gifford AN, Bruneus M, Gatley SJ, Lan R, Makriyannis A, Volkow ND (1999). Large receptor reserve for cannabinoid actions in the central nervous system. J Pharmacol Exp Ther 288 : 478 483.
39. 2 receptors: immunohistochemical localization in rat brain. Brain Res 1071 : 10 23. (Pubitemid 43255471)
40. 2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. Br J Pharmacol 153 : 319 334.
41. Gustafsson K, Wang X, Severa D, Eriksson M, Kimby E, Merup M et al. (2008). Expression of cannabinoid receptors type 1 and type 2 in non-Hodgkin lymphoma: growth inhibition by receptor activation. Int J Cancer 123 : 1025 1033.
42. Guzmán M (2003). Cannabinoids: potential anticancer agents. Nat Rev Cancer 3 : 745 755.
43. Hermann H, Marsicano G, Lutz B (2002). Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain. Neuroscience 109 : 451 460.
44. Holdcroft A, Smith M, Jacklin A, Hodgson H, Smith B, Newton M et al. (1997). Pain relief with oral cannabinoids in familial Mediterranean fever. Anaesthesia 52 : 483 488.
45. 1 receptors with hypophagic effects in rats. Br J Pharmacol 152 : 805 814.
46. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA et al. (2002). International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54 : 161 202.
47. 9- tetrahydrocannabinol-induced impairment of spatial memory and reduction of acetylcholine release in the dorsal hippocampus in rats. Neurotox Res 6 : 153 158.
48. Izzo AA, Camilleri M (2008). Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects. Gut 57 : 1140 1155.
49. Izzo AA, Coutts AA (2005). Cannabinoids and the digestive tract. In : Pertwee RG (ed.). Cannabinoids. Handbook of Experimental Pharmacology, Vol. 168. Springer-Verlag : Heidelberg, pp. 573 598.
50. 1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. Br J Pharmacol 134 : 563 570.
51. Izzo AA, Capasso F, Costagliola A, Bisogno T, Marsicano G, Ligresti A et al. (2003). An endogenous cannabinoid tone attenuates cholera toxin-induced fluid accumulation in mice. Gastroenterology 125 : 765 774.
52. Jafari MR, Ghiasvand F, Golmohammadi S, Zarrindast MR, Djahanguiri B (2008). Influence of central nicotinic receptors on arachidonylcyclopropylamide (ACPA)-induced antinociception in mice. Int J Neurosci 118 : 531 543.
53. 2 receptors in the thalamus of neuropathic rats. Eur J Neurosci 27 : 1722 1730.
54. Jin KL, Mao XO, Goldsmith PC, Greenberg DA (2000). CB1 cannabinoid receptor induction in experimental stroke. Ann Neurol 48 : 257 261.
55. Johns DG, Behm DJ, Walker DJ, Ao Z, Shapland EM, Daniels DA et al. (2007). The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects. Br J Pharmacol 152 : 825 831.
56. Kang S, Kim CH, Lee H, Kim DY, Han JI, Chung RK et al. (2007). Antinociceptive synergy between the cannabinoid receptor agonist WIN 55,212-2 and bupivacaine in the rat formalin test. Anesth Analg 104 : 719 725.
57. Karst M, Salim K, Burstein S, Conrad I, Hoy L, Schneider U (2003). Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain. A randomized controlled trial. J Am Med Assoc 290 : 1757 1762.
58. 2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis. Eur J Pharmacol 542 : 100 105.
59. Kimball ES, Schneider CR, Wallace NH, Hornby PJ (2006). Agonists of cannabinoid receptor 1 and 2 inhibit experimental colitis induced by oil of mustard and by dextran sulfate sodium. Am J Physiol Gastrointest Liver Physiol 291 : G364 G371.
60. Kraft B, Frickey NA, Kaufmann RM, Reif M, Frey R, Gustorff B et al. (2008). Lack of analgesia by oral standardized cannabis extract on acute inflammatory pain and hyperalgesia in volunteers. Anesthesiology 109 : 101 110.
61. Kwiatkowska M, Parker LA, Burton P, Mechoulam R (2004). A comparative analysis of the potential of cannabinoids and ondansetron to suppress cisplatin-induced emesis in the Suncus murinus (house musk shrew). Psychopharmacology 174 : 254 259.
62. Lauckner JE, Jensen JB, Chen H-Y, Lu H-C, Hille B, Mackie K (2008). GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci USA 105 : 2699 2704.
63. 1 receptor antagonists as promising new medications for drug dependence. J Pharmacol Exp Ther 312 : 875 883.
64. 9-tetrahydrocannabinol and μ opioid receptor agonists in rhesus monkeys: discrimination and antinociception. Psychopharmacology 199 : 199 208.
65. Lim G, Sung B, Ji R-R, Mao J (2003). Upregulation of spinal cannabinoid-1-receptors following nerve injury enhances the effects of Win 55,212-2 on neuropathic pain behaviors in rats. Pain 105 : 275 283.
66. Lotersztajn S, Teixeira-Clerc F, Julien B, Deveaux V, Ichigotani Y, Manin S et al. (2008). CB2 receptors as new therapeutic targets for liver diseases. Br J Pharmacol 153 : 286 289.
67. 2 receptor inverse agonists. Br J Pharmacol 153 : 226 239.
68. Mach F, Montecucco F, Steffens S (2008). Cannabinoid receptors in acute and chronic complications of atherosclerosis. Br J Pharmacol 153 : 290 298.
69. Mallat A, Teixeira-Clerc F, Deveaux V, Lotersztajn S (2007). Cannabinoid receptors as new targets of antifibrosing strategies during chronic liver diseases. Expert Opin Ther Targets 11 : 403 409.
70. 9-tetrahydrocannabinol-induced hypothermia in the rat. Pharmacol Biochem Behav 69 : 595 601.
71. Manzanedo C, Aguilar MA, Rodríguez-Arias M, Navarro M, Miñarro J (2004). Cannabinoid agonist-induced sensitisation to morphine place preference in mice. Neuroreport 15 : 1373 1377.
72. 9-THC-treated rats: possible clinical implications. Br J Pharmacol 140 : 520 526.
73. 2 receptor in microglial cells in response to inflammatory stimuli. J Neurochem 95 : 437 445.
74. Massa F, Marsicano G, Hermann H, Cannich A, Monory K, Cravatt BF et al. (2004). The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest 113 : 1202 1209.
75. Mechoulam R (1986). The pharmacohistory of Cannabis sativa. In : Mechoulam R (ed.). Cannabinoids as Therapeutic Agents. CRC Press : Boca Raton, pp. 1 19.
76. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR et al. (1995). Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50 : 83 90.
77. Mitchell VA, Aslan S, Safaei R, Vaughan CW (2005). Effect of the cannabinoid ajulemic acid on rat models of neuropathic and inflammatory pain. Neurosci Lett 382 : 231 235.
78. Mitrirattanakul S, Ramakul N, Guerrero AV, Matsuka Y, Ono T, Iwase H et al. (2006). Site-specific increases in peripheral cannabinoid receptors and their endogenous ligands in a model of neuropathic pain. Pain 126 : 102 114.
79. 3A) are co-expressed in GABA neurons in the rat telencephalon. J Comp Neurol 468 : 205 216.
80. Naderi N, Haghparast A, Saber-Tehrani A, Rezaii N, Alizadeh A-M, Khani A et al. (2008). Interaction between cannabinoid compounds and diazepam on anxiety-like behaviour of mice. Pharmacol Biochem Behav 89 : 64 75.
81. Naef M, Curatolo M, Petersen-Felix S, Arendt-Nielsen L, Zbinden A, Brenneisen R (2003). The analgesic effect of oral delta-9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions. Pain 105 : 79 88.
82. Narang S, Gibson D, Wasan AD, Ross EL, Michna E, Nedelikovic SS et al. (2008). Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy. J Pain 9 : 254 264.
83. Ni X, Geller EB, Eppihimer MJ, Eisenstein TK, Adler MW, Tuma RF (2004). Win 55212-2, a cannabinoid receptor agonist, attenuates leukocyte/endothelial interactions in an experimental autoimmune encephalomyelitis model. Mult Scler 10 : 158 164.
84. Oka S, Nakajima K, Yamashita A, Kishimoto S, Sugiura T (2007). Identification of GPR55 as a lysophosphatidylinositol receptor. Biochem Biophys Res Commun 362 : 928 934.
85. Onaivi ES (2006). Neuropsychobiological evidence for the functional presence and expression of cannabinoid CB2 receptors in the brain. Neuropsychobiology 54 : 231 246.
86. Pacher P, Hasko G (2008). Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning. Br J Pharmacol 153 : 252 262.
87. Paquette JJ, Wang H-Y, Bakshi K, Olmstead MC (2007). Cannabinoid-induced tolerance is associated with a CB1 receptor G protein coupling switch that is prevented by ultra-low dose rimonabant. Behav Pharmacol 18 : 767 776.
88. Pertwee RG (1992). In vivo interactions between psychotropic cannabinoids and other drugs involving central and peripheral neurochemical mediators. In : Murphy L, Bartke A (eds). Marijuana/Cannabinoids. Neurobiology and Neurophysiology. CRC Press : Boca Raton, pp. 165 218.
89. Pertwee RG (1999). Pharmacology of cannabinoid receptor ligands. Curr Med Chem 6 : 635 664.
90. Pertwee RG (2001). Cannabinoid receptors and pain. Prog Neurobiol 63 : 569 611.
91. Pertwee RG (2005a). The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. AAPS J 7 : E625 E654.
92. Pertwee RG (2005b). Pharmacological actions of cannabinoids. In : Pertwee RG (ed.). Cannabinoids. Handbook of Experimental Pharmacology, Vol. 168. Springer-Verlag : Heidelberg, pp. 1 51.
93. 1 receptors. Life Sci 76 : 1307 1324.
94. Pertwee RG (2006). Cannabinoid pharmacology: the first 66 years. Br J Pharmacol 147 : S163 S171.
95. Pertwee RG (2007a). Cannabinoids and multiple sclerosis. Mol Neurobiol 36 : 45 59.
96. Pertwee RG (2007b). GPR55: a new member of the cannabinoid receptor clan? Br J Pharmacol 152 : 984 986.
97. 9- tetrahydrocannabivarin. Br J Pharmacol 153 : 199 215.
98. Pertwee RG (2008b). Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond. Addict Biol 13 : 147 159.
99. Pertwee RG, Ross RA (2002). Cannabinoid receptors and their ligands. Prostaglandins Leukot Essent Fatty Acids 66 : 101 121.
100. Pertwee RG, Thomas A (2009). Therapeutic applications for agents that act at CB1 and CB2 receptors. In : Reggio P (ed.). The Cannabinoid Receptors. Humana Press : Totowa, pp. 361 392.
101. Potenzieri C, Harding-Rose C, Simone DA (2008). The cannabinoid receptor agonist, WIN 55, 212-2, attenuates tumor-evoked hyperalgesia through peripheral mechanisms. Brain Res 1215 : 69 75.
102. 1 receptor. Mol Pharmacol 68 : 1484 1495.
103. 9-tetrahydrocannabinol-induced analgesia by morphine in mice: involvement of μ- and κ-opioid receptors. Eur J Pharmacol 318 : 11 16. (Pubitemid 27033197)
104. Roberts JD, Gennings C, Shih M (2006). Synergistic affective analgesic interaction between delta-9-tetrahydrocannabinol and morphine. Eur J Pharmacol 530 : 54 58.
105. Robledo P, Trigo JM, Panayi F, de la Torre R, Maldonado R (2007). Behavioural and neurochemical effects of combined MDMA and THC administration in mice. Psychopharmacology 195 : 255 264.
106. Romero-Sandoval A, Eisenach JC (2007). Spinal cannabinoid receptor type 2 activation reduces hypersensitivity and spinal cord glial activation after paw incision. Anesthesiology 106 : 787 794.
107. Ross RA (2007). Allosterism and cannabinoid CB1 receptors: the shape of things to come. Trends Pharmacol Sci 28 : 567 572.
108. Ross RA, Coutts AA, McFarlane SM, Anavi-Goffer S, Irving AJ, Pertwee RG et al. (2001). Actions of cannabinoid receptor ligands on rat cultured sensory neurones: implications for antinociception. Neuropharmacology 40 : 221 232.
109. Rubio-Araiz A, Arévalo-Martín A, Gómez-Torres O, Navarro-Galve B, García-Ovejero D, Suetterlin P et al. (2008). The endocannabinoid system modulates a transient TNF pathway that induces neural stem cell proliferation. Mol Cell Neurosci 38 : 374 380.
110. Rukwied R, Watkinson A, McGlone F, Dvorak M (2003). Cannabinoid agonists attenuate capsaicin-induced responses in human skin. Pain 102 : 283 288. (Pubitemid 36369307)
111. Ryberg E, Larsson N, Sjögren S, Hjorth S, Hermansson N-O, Leonova J et al. (2007). The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152 : 1092 1101.
112. Sagredo O, García-Arencibia M, de Lago E, Finetti S, Decio A, Fernández-Ruiz J (2007). Cannabinoids and neuroprotection in basal ganglia disorders. Mol Neurobiol 36 : 82 91.
113. Salim K, Schneider U, Burstein S, Hoy L, Karst M (2005). Pain measurements and side effect profile of the novel cannabinoid ajulemic acid. Neuropharmacology 48 : 1164 1171.
114. Sarfaraz S, Afaq F, Adhami VM, Mukhtar H (2005). Cannabinoid receptor as a novel target for the treatment of prostate cancer. Cancer Res 65 : 1635 1641.
115. 9-tetrahydrocannabinol and the opioid receptor agonist piritramide do not act synergistically in postoperative pain. Anaesthesist 55 : 391 400.
116. Shoemaker JL, Seely KA, Reed RL, Crow JP, Prather PL (2007). The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. J Neurochem 101 : 87 98.
117. 1 receptor upregulation in a rat model of chronic neuropathic pain. Eur J Pharmacol 415 : R5 R7.
118. 9-tetrahydrocannabinol alters heroin-induced locomotor sensitisation and Fos-immunoreactivity. Neuropharmacology 49 : 1189 1200.
119. Skaper SD, Buriani A, Dal Toso R, Petrelli L, Romanello S, Facci L et al. (1996). The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. Proc Natl Acad Sci USA 93 : 3984 3989.
120. 9-tetrahydrocannabinol circumvents antinociceptive tolerance and apparent desensitization of receptors. Eur J Pharmacol 571 : 129 137.
121. Ständer S, Schmelz M, Metze D, Luger T, Rukwied R (2005). Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin. J Dermatol Sci 38 : 177 188.
122. Steffens S, Veillard NR, Arnaud C, Pelli G, Burger F, Staub C et al. (2005). Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature 434 : 782 786.
123. Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K et al. (1995). 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Comm 215 : 89 97.
124. Svendsen KB, Jensen TS, Bach FW (2004). Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. Br Med J 329 : 253 257.
125. Szabo B, Schlicker E (2005). Effects of cannabinoids on neurotransmission. In : Pertwee RG (ed.). Cannabinoids. Springer-Verlag : Heidelberg, pp. 327 365.
126. 1 receptor antagonist and selective serotonin reuptake inhibitor in antidepressant behavioral tests. Eur J Pharmacol 589 : 149 156.
127. 2-adrenoceptor agonists in acute pain models in mice. Br J Pharmacol 144 : 875 884.
128. 9-tetrahydrocannabinol and nicotine. Br J Pharmacol 135 : 564 578.
129. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rössner S (2005). Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365 : 1389 1397. (Pubitemid 40523733)
130. 1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study. Eur Heart J 29 : 1761 1771.
131. 2 receptors. Science 310 : 329 332.
132. Wade DT, Makela P, Robson P, House H, Bateman C (2004). Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 10 : 434 441.
133. Wager-Miller J, Westenbroek R, Mackie K (2002). Dimerization of G protein-coupled receptors: CB1 cannabinoid receptors as an example. Chem Phys Lipids 121 : 83 89.
134. Walczak J-S, Pichette V, Leblond F, Desbiens K, Beaulieu P (2005). Behavioral, pharmacological and molecular characterization of the saphenous nerve partial ligation: a new model of neuropathic pain. Neuroscience 132 : 1093 1102.
135. Walczak J-S, Pichette V, Leblond F, Desbiens K, Beaulieu P (2006). Characterization of chronic constriction of the saphenous nerve, a model of neuropathic pain in mice showing rapid molecular and electrophysiological changes. J Neurosci Res 83 : 1310 1322.
136. Walker JM, Hohmann AG (2005). Cannabinoid mechanisms of pain suppression. In : Pertwee RG (ed.). Cannabinoids. Handbook of Experimental Pharmacology. Springer-Verlag : Heidelberg, pp. 509 554.
137. Wallace MJ, Blair RE, Falenski KW, Martin BR, DeLorenzo RJ (2003). The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy. J Pharmacol Exp Ther 307 : 129 137.
138. Walter L, Stella N (2004). Cannabinoids and neuroinflammation. Br J Pharmacol 141 : 775 785.
139. Wang D, Wang H, Ning W, Backlund MG, Dey SK, DuBois RN (2008). Loss of cannabinoid receptor 1 accelerates intestinal tumor growth. Cancer Res 68 : 6468 6476.
140. Whiteside GT, Lee GP, Valenzano KJ (2007). The role of the cannabinoid CB2 receptor in pain transmission and therapeutic potential of small molecule CB2 receptor agonists. Curr Med Chem 14 : 917 936.
141. 2-selective agonists. J Pharmacol Exp Ther 301 : 679 689.
142. 9-tetrahydrocannabinol. Eur J Pharmacol 539 : 57 63.
143. Wotherspoon G, Fox A, McIntyre P, Colley S, Bevan S, Winter J (2005). Peripheral nerve injury induces cannabinoid receptor 2 protein expression in rat sensory neurons. Neuroscience 135 : 235 245.
144. 2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation. Br J Pharmacol 153 : 263 270.
145. Xu H, Cheng CL, Chen M, Manivannan A, Cabay L, Pertwee RG et al. (2007). Anti-inflammatory property of the cannabinoid receptor-2-selective agonist JWH-133 in a rodent model of autoimmune uveoretinitis. J Leukoc Biol 82 : 532 541.
146. Xu X, Liu Y, Huang S, Liu G, Xie C, Zhou J et al. (2006). Overexpression of cannabinoid receptors CB1 and CB2 correlates with improved prognosis of patients with hepatocellular carcinoma. Cancer Genet Cytogenet 171 : 31 38.
147. 2 receptor in reducing mechanical allodynia in a mouse model of neuropathic pain. Eur J Pharmacol 583 : 56 61.
148. 2 receptor? Br J Pharmacol 149 : 145 154.
149. Yesilyurt O, Dogrul A, Gul H, Seyrek M, Kusmez O, Ozkan Y et al. (2003). Topical cannabinoid enhances topical morphine antinociception. Pain 105 : 303 308. (Pubitemid 37162500)
150. Yiangou Y, Facer P, Durrenberger P, Chessell IP, Naylor A, Bountra C et al. (2006). COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol 6 Available at: http://www.biomedcentral.com/ 1471-2377/6/12 (accessed MH, Choi JI (2003). Pharmacologic interaction between cannabinoid and either clonidine or neostigmine in the rat formalin test. Anesthesiology 99 : 701 707.
151. Young JM, McGregor IS, Mallet PE (2005). Co-administration of THC and MDMA ('Ecstasy') synergistically disrupts memory in rats. Neuropsychopharmacology 30 : 1475 1482.
152. Zhang J, Hoffert C, Vu HK, Groblewski T, Ahmad S, O'Donnell D (2003). Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models. Eur J Neurosci 17 : 2750 2754.
153. 2 receptor activation decreases cerebral infarction in a mouse focal ischemia/reperfusion model. J Cereb Blood Flow Metab 27 : 1387 1396.
154. 2 receptor activation during cerebral ischemic/reperfusion injury. Neuroscience 152 : 753 760.